ORPHAN Cures Act
Latest action · Feb 6, 2025 Sponsor introductory remarks on measure. (CR H535-536)
Progress
Where this bill reached, and when. A stage with no date was not reached; one that failed a vote and later carried shows the date it carried.
- IntroducedFeb 4, 2025
- Passed HouseNot reached
- Passed SenateNot reached
- To the PresidentNot reached
- Became lawNot reached
Summary
Optimizing Research Progress Hope And New Cures Act or the ORPHAN Cures Act
This bill modifies certain provisions under the Medicare Drug Price Negotiation Program with respect to orphan drugs.
The Medicare Drug Price Negotiation Program requires the Centers for Medicare & Medicaid Services to negotiate the prices of certain prescription drugs under Medicare beginning in 2026. Among other requirements, drugs must have had market approval for at least 7 years (for drug products) or 11 years (for biologics) to qualify for negotiation. The program does not apply to orphan drugs that are approved to treat only one rare disease or condition.
The bill modifies these provisions so as to exclude any period in which a drug was an orphan drug from market approval calculations. It also excludes orphan drugs that are approved to treat more than one rare disease or condition from the program.
Cosponsors 18
Members who signed on, in the order they did. Signatures ran from Feb 4, 2025 to Sep 30, 2025; 9 are original cosponsors, there from the day it was introduced.
| Seat | Cosponsor | Signed on | |
|---|---|---|---|
| D-NC | Donald G. Davis | Original | Feb 4, 2025 |
| R-FL | Gus M. Bilirakis | Original | Feb 4, 2025 |
| D-NJ | Josh Gottheimer | Original | Feb 4, 2025 |
| R-OK | Kevin Hern | Original | Feb 4, 2025 |
| R-IA | Mariannette Miller-Meeks | Original | Feb 4, 2025 |
| R-NC | Richard Hudson | Original | Feb 4, 2025 |
| D-CA | Scott H. Peters | Original | Feb 4, 2025 |
| D-MI | Shri Thanedar | Original | Feb 4, 2025 |
| D-MA | William R. Keating | Original | Feb 4, 2025 |
| D-NV | Dina Titus | Apr 7, 2025 | |
| D-OR | Janelle S. Bynum | Apr 7, 2025 | |
| R-PA | Lloyd Smucker | Apr 7, 2025 | |
| R-NJ | Thomas H. Kean, Jr. | Apr 7, 2025 | |
| D-OR | Andrea Salinas | May 20, 2025 | |
| R-FL | Neal P. Dunn | May 20, 2025 | |
| D-CA | Adam Gray | Jun 12, 2025 | |
| R-TX | Dan Crenshaw | Jun 12, 2025 | |
| R-PA | Robert P. Bresnahan, Jr. | Sep 30, 2025 |
Committees 2
Where it was sent and what each committee and subcommittee did with it, in order.
| Chamber | Committee | What it did |
|---|---|---|
| House | Energy and Commerce Committee | Referred Feb 4, 2025 |
| House | Ways and Means Committee | Referred Feb 4, 2025 |
Actions 3
Everything that happened, newest first.
- Feb 6, 2025Sponsor introductory remarks on measure. (CR H535-536)
- Feb 4, 2025Introduced in House
- Feb 4, 2025Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
In the Congressional Record 1
Days the Record’s own index lists this bill, newest first, with the pages and the members it names. Pages starting H are the House, S the Senate, E Extensions of Remarks.
| Where | In the Record | Members | Date |
|---|---|---|---|
| House | Debate and remarks H535 | John Joyce R-PA | Feb 6, 2025 |
Research
What has been written about this bill: committee reports, cost estimates, the sponsor’s authority statement, printed hearings and the Congressional Research Service’s work.
Constitutional authority
The sponsor’s statement, as printed in the Congressional Record, vol. 171, no. 23, February 4, 2025, page H460.
Related bills 1
Companion bills and other measures the record links to this one.
| Bill | Title | Relationship | Latest action |
|---|---|---|---|
| S 1862 | ORPHAN Cures Act | Related bill | May 22, 2025 |
Titles 3
Every title it has carried, official and short, at each stage.
- Official Title as Introduced
- To amend title XI of the Social Security Act to expand and clarify the exclusion for orphan drugs under the Drug Price Negotiation Program.
- Short Title(s) as Introduced
- ORPHAN Cures Act
- Optimizing Research Progress Hope And New Cures Act
Subjects
Assigned by the Library of Congress. Policy area: Health.
Text 1
Each version as it was printed, newest first.
- Feb 4, 2025Introduced in House
Support LegiList
This page is free, carries no paywall, and is built and maintained by one person. If the record here is useful to you, a few dollars keeps it going.
Everything here is as published by Congress: the summary is the Congressional Research Service's, the action wording is the clerks', and the subjects are the Library of Congress's. How far it got is read from the actions themselves, taking the most recent one of each kind, so a bill that failed a vote and later passed is shown as having passed. Records come from this bill on Congress.gov and govinfo.gov; cost estimates are the Congressional Budget Office's, and the hearings are the printed hearings GovInfo publishes, which can appear months after the hearing.